Our fibrosis collaborations
In January 2019 we announced a global collaboration with Fibrocor focused on novel targets in IPF. Fibrocor is responsible for all research activities until lead optimization, and we are responsible for the further development and commercialization of the in-licensed programs. Galapagos took an undisclosed equity stake in Fibrocor (privately held).
In November 2020 we entered into an exclusive collaboration and license agreement with OncoArendi Therapeutics for the global development and commercialization of GLPG4716, a chitinase inhibitor, in IPF. Under the terms of the agreement, we are responsible for the further development and commercialization of the program. In addition, we have the option to initiate negotiations to obtain development or commercialization rights for selected preclinical candidate molecules.
In October 2018, we and AbbVie amended and restated our collaboration agreement whereby AbbVie took over all programs in CF. AbbVie obtained exclusive worldwide rights to the current CF investigational drug candidate portfolio developed by the two companies in the course of the collaboration, with the exception of GLPG1837 and GLPG2737. We retain rights to these two compounds for use outside the field of CF. AbbVie will be responsible for all future activities and will bear all costs associated with the CF portfolio. We will be eligible to receive additional milestone payments pending completion of certain development, regulatory, and commercial milestones in CF by AbbVie. In the event AbbVie receives regulatory approval and realizes commercial sales in CF, we are eligible to receive royalties ranging from single digit to low teens. AbbVie further agrees to pay us, if approved, tiered single digit royalties on global commercial sales from the candidate indications outside of CF.